Mirum Pharmaceuticals, Inc. announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older… read more.
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive… read more.
Children living with sickle cell anaemia have no higher incidence of clinically diagnosed infections when treated with hydroxyurea. New research shows the efficacy and safety of hydroxyurea treatment… read more.
Pharmacies across the United States continue to close at a rapid rate, leaving millions of Americans in “pharmacy deserts,” where they lack convenient and reasonable access to the… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved catumaxomab (Korjuny) to treat malignant ascites in adults when standard treatment of their cancer is no longer feasible…. read more.
NICE(UK): Daratumumab plus bortezomib, lenalidomide and dexamethasone as induction and consolidation treatment, followed by daratumumab plus lenalidomide as maintenance treatment, can be used as an option for untreated multiple… read more.
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced (12th October 2026) that interim results from its V012… read more.
No hospitalized patient loves getting a urinary catheter. But if they must have one, the last thing they want is a urinary tract infection caused by bacteria that… read more.
More U.S. women are being prescribed GLP-1 medications after giving birth, particularly those diagnosed with diabetes, according to new research from the USC Schaeffer Center for Health Policy… read more.
Sarepta Therapeutics, Inc. presented new data at the 31st Annual Congress of the World Muscle Society (WMS) that provide evidence of clinically meaningful functional benefit of ELEVIDYS (delandistrogene… read more.
Johnson & Johnson announced that TREMFYA (guselkumab) met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflammation by MRI assessment in… read more.
11th October 2026 – AbbVie announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
